Xeris Biopharma Holdings, Inc. — All Filings
280 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
4/A
424B3
424B5
425
8-K
8-K12B
ARS
CORRESP
DEF 14A
DEFA14A
EFFECT
S-3
S-4
S-4/A
S-8
SC 13G
SC 13G/A
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | FORM 4 | 0001867096-22-000090 | Jun 9, 2022 | Jun 8, 2022 |
| 8-K | 8-K | 0001867096-22-000070 | Jun 8, 2022 | — |
| 4 | FORM 4 | 0001867096-22-000067 | May 13, 2022 | May 12, 2022 |
| 424B5 | 424B5 | 0001193125-22-147610 | May 11, 2022 | — |
| 10-Q | 10-Q | 0001867096-22-000063 | May 11, 2022 | Mar 31, 2022 |
| 8-K | 8-K | 0001867096-22-000056 | May 11, 2022 | — |
| DEFA14A | DEFA14A | 0001867096-22-000050 | May 2, 2022 | — |
| DEFA14A | DEFA14A | 0001867096-22-000048 | Apr 28, 2022 | — |
| DEF 14A | DEF 14A | 0001867096-22-000047 | Apr 28, 2022 | Dec 31, 2021 |
| S-8 | S-8 | 0001867096-22-000042 | Mar 11, 2022 | — |
| 10-K | 10-K | 0001867096-22-000040 | Mar 11, 2022 | Dec 31, 2021 |
| 8-K | 8-K | 0001867096-22-000033 | Mar 10, 2022 | Mar 8, 2022 |
| 4 | FORM 4 | 0001867096-22-000025 | Feb 24, 2022 | Feb 22, 2022 |
| SC 13G/A | — | 0001193805-22-000261 | Feb 11, 2022 | — |
| 424B3 | 424B3 | 0001628280-22-001944 | Feb 8, 2022 | — |
| EFFECT | — | 9999999995-22-000355 | Feb 7, 2022 | — |
| EFFECT | — | 9999999995-22-000356 | Feb 7, 2022 | — |
| CORRESP | — | 0001628280-22-001856 | Feb 4, 2022 | — |
| CORRESP | — | 0001628280-22-001855 | Feb 4, 2022 | — |
| UPLOAD | — | 0000000000-22-001313 | Feb 1, 2022 | — |
| UPLOAD | — | 0000000000-22-001311 | Feb 1, 2022 | — |
| S-3 | S-3 | 0001628280-22-001449 | Jan 28, 2022 | — |
| S-3 | S-3 | 0001628280-22-001447 | Jan 28, 2022 | — |
| 8-K | 8-K | 0001867096-22-000023 | Jan 28, 2022 | — |
| 8-K | 8-K | 0001867096-22-000017 | Jan 18, 2022 | — |
| SC 13G | — | 0000935836-22-000016 | Jan 14, 2022 | — |
| 4 | FORM 4 | 0001867096-22-000012 | Jan 5, 2022 | Jan 3, 2022 |
| 4 | FORM 4 | 0001867096-22-000010 | Jan 5, 2022 | Jan 3, 2022 |
| 4 | FORM 4 | 0001867096-22-000009 | Jan 5, 2022 | Jan 3, 2022 |
| 4 | FORM 4 | 0001867096-22-000008 | Jan 5, 2022 | Jan 3, 2022 |
| 4 | FORM 4 | 0001867096-22-000007 | Jan 5, 2022 | Jan 3, 2022 |
| 4 | FORM 4 | 0001867096-22-000006 | Jan 5, 2022 | Jan 3, 2022 |
| SC 13G | — | 0000919574-22-000042 | Jan 5, 2022 | — |
| 8-K | 8-K | 0001193125-22-000317 | Jan 3, 2022 | Jan 2, 2022 |
| 4 | FORM 4 | 0001867096-21-000080 | Nov 16, 2021 | Nov 15, 2021 |
| 4 | FORM 4 | 0001867096-21-000077 | Nov 12, 2021 | Nov 11, 2021 |
| 4 | FORM 4 | 0001867096-21-000076 | Nov 12, 2021 | Nov 11, 2021 |
| 4 | FORM 4 | 0001867096-21-000075 | Nov 12, 2021 | Nov 10, 2021 |
| 10-Q | 10-Q | 0001867096-21-000069 | Nov 10, 2021 | Sep 30, 2021 |
| 8-K | 8-K | 0001867096-21-000066 | Nov 10, 2021 | — |
| 4/A | FORM 4/A SUBMISSION | 0000899243-21-039750 | Oct 8, 2021 | Oct 5, 2021 |
| 4/A | FORM 4/A SUBMISSION | 0000899243-21-039749 | Oct 8, 2021 | Oct 5, 2021 |
| 8-K | 8-K | 0001193125-21-294870 | Oct 8, 2021 | Oct 5, 2021 |
| 4 | FORM 4 SUBMISSION | 0000899243-21-039342 | Oct 5, 2021 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-21-039341 | Oct 5, 2021 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-21-039340 | Oct 5, 2021 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-21-039338 | Oct 5, 2021 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-21-039335 | Oct 5, 2021 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-21-039333 | Oct 5, 2021 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-21-039330 | Oct 5, 2021 | — |